Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2023-03-20
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effects of acalabrutinib, umbralisib, and ublituximab in
treating previously untreated mantle cell lymphoma. Acalabrutinib and umbralisib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. Ublituximab is
a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
Giving acalabrutinib and umbralisib with ublituximab may work better in treating mantle cell
lymphoma.